Omega-3 fatty acid supplementation does not reduce risk
of atrial fibrillation after coronary artery bypass surgery:
a randomized, double-blind, placebo-controlled clinical trial
Omega-3 fatty acid supplementation does not reduce risk
of atrial fibrillation after coronary artery bypass surgery:
a randomized, double-blind, placebo-controlled clinical trial
Background—Omega-3 polyunsaturated fatty acids (n-3 PUFA) have been reported to reduce the risk of sudden cardiac
death presumed to be due to fatal ventricular arrhythmias, but their effect on atrial arrhythmias is unclear.
Methods and Results—Patients (n108) undergoing coronary artery bypass graft surgery were randomly assigned to
receive 2 g/d n-3 PUFA or placebo (olive oil) for at least 5 days before surgery (median, 16 days; range, 12 to 21
days). Phospholipid n-3 PUFA were measured in serum at study entry and at surgery and in right atrial appendage
tissue at surgery. Echocardiography was used to assess left ventricular function and left atrial dimensions.
Postoperative continuous ECG monitoring (Lifecard CF) for 5 days or until discharge, if earlier, was performed
with a daily 12-lead ECG and clinical review if patients remained in the hospital beyond 5 days. Lifecard
recordings were analyzed for episodes of atrial fibrillation (AF) 30 seconds (primary outcome). Clinical AF, AF
burden (% time in AF), hospital stay, and intensive care/high dependency care stay were measured as secondary
outcomes. One hundred three patients completed the study (51 in the placebo group and 52 in the n-3 PUFA group).
There were no clinically relevant differences in baseline characteristics between groups. n-3 PUFA levels were
higher in serum and right atrial tissue in the active treatment group. There was no significant difference between
groups in the primary outcome of AF (95% confidence interval [CI], 6% to 30%, P0.28) in any of the
secondary outcomes or in AF-free survival.
Conclusions—Omega-3 PUFA do not reduce the risk of AF after coronary artery bypass graft surgery.
46-53
Saravanan, Palanaippan
d0feff49-10e3-4637-9413-da88129303f7
Bridgewater, Ben
63088632-97b9-4eff-9446-a47fc2191aa3
West, Annette L.
c1923242-802f-4331-b743-31de45d3883c
O'Neill, Stephen C.
370930da-10e8-48b4-bc00-962d1e43bc04
Calder, Philip C.
1797e54f-378e-4dcb-80a4-3e30018f07a6
Davidson, Neil C.
31a26738-1c66-424f-bad1-7314d3f50a2b
February 2010
Saravanan, Palanaippan
d0feff49-10e3-4637-9413-da88129303f7
Bridgewater, Ben
63088632-97b9-4eff-9446-a47fc2191aa3
West, Annette L.
c1923242-802f-4331-b743-31de45d3883c
O'Neill, Stephen C.
370930da-10e8-48b4-bc00-962d1e43bc04
Calder, Philip C.
1797e54f-378e-4dcb-80a4-3e30018f07a6
Davidson, Neil C.
31a26738-1c66-424f-bad1-7314d3f50a2b
Saravanan, Palanaippan, Bridgewater, Ben, West, Annette L., O'Neill, Stephen C., Calder, Philip C. and Davidson, Neil C.
(2010)
Omega-3 fatty acid supplementation does not reduce risk
of atrial fibrillation after coronary artery bypass surgery:
a randomized, double-blind, placebo-controlled clinical trial.
Circulation: Arrhythmia and Electrophysiology, 3, .
(doi:10.1161/CIRCEP.109.899633).
Abstract
Background—Omega-3 polyunsaturated fatty acids (n-3 PUFA) have been reported to reduce the risk of sudden cardiac
death presumed to be due to fatal ventricular arrhythmias, but their effect on atrial arrhythmias is unclear.
Methods and Results—Patients (n108) undergoing coronary artery bypass graft surgery were randomly assigned to
receive 2 g/d n-3 PUFA or placebo (olive oil) for at least 5 days before surgery (median, 16 days; range, 12 to 21
days). Phospholipid n-3 PUFA were measured in serum at study entry and at surgery and in right atrial appendage
tissue at surgery. Echocardiography was used to assess left ventricular function and left atrial dimensions.
Postoperative continuous ECG monitoring (Lifecard CF) for 5 days or until discharge, if earlier, was performed
with a daily 12-lead ECG and clinical review if patients remained in the hospital beyond 5 days. Lifecard
recordings were analyzed for episodes of atrial fibrillation (AF) 30 seconds (primary outcome). Clinical AF, AF
burden (% time in AF), hospital stay, and intensive care/high dependency care stay were measured as secondary
outcomes. One hundred three patients completed the study (51 in the placebo group and 52 in the n-3 PUFA group).
There were no clinically relevant differences in baseline characteristics between groups. n-3 PUFA levels were
higher in serum and right atrial tissue in the active treatment group. There was no significant difference between
groups in the primary outcome of AF (95% confidence interval [CI], 6% to 30%, P0.28) in any of the
secondary outcomes or in AF-free survival.
Conclusions—Omega-3 PUFA do not reduce the risk of AF after coronary artery bypass graft surgery.
Text
336_Saravanan_et_al_Circ_Arrhyth_Electrophysiol.pdf
- Version of Record
Restricted to Registered users only
Request a copy
More information
Submitted date: 4 August 2009
Published date: February 2010
Identifiers
Local EPrints ID: 72922
URI: http://eprints.soton.ac.uk/id/eprint/72922
PURE UUID: 740293ec-dede-4e33-9bc9-3506345e8457
Catalogue record
Date deposited: 25 Feb 2010
Last modified: 14 Mar 2024 02:50
Export record
Altmetrics
Contributors
Author:
Palanaippan Saravanan
Author:
Ben Bridgewater
Author:
Annette L. West
Author:
Stephen C. O'Neill
Author:
Neil C. Davidson
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics